2021 CMSC Annual Meeting

Tag: MBA

Poster-Quality of Life and Outcomes

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis

Background: Employers offer a variety of absence benefits. It is unknown how benefit design impacts the use of the benefits, the length of...

Read More

Poster-Quality of Life and Outcomes

A Coach Supported Standardized Approach for Quality Improvement (QI) in the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Research Collaborative.

Background: MS-CQI is the first multicenter improvement research collaborative for MS. MS-CQI was a three-year study (2018-2020) of...

Read More

Poster-Quality of Life and Outcomes

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More

Poster-Methods of Care

Floodlight MS: Using the Jobs-to-be-Done Framework to Identify Unmet Needs in Multiple Sclerosis Care to Support Digital Medical Device Development

Background: Multiple sclerosis (MS) is a chronic disease, and people living with MS (PLwMS) often experience symptoms across numerous...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans

Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...

Read More

Poster-Disease-modifying Therapy

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More

Platform-Disease Management

How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey

Background: The COVID-19 crisis has created unanticipated changes in health care delivery for people living with multiple sclerosis (MS)....

Read More